MedPath
Found 1012 clinical trials|View Analysis
Sort by:

A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Phase 2
Not yet recruiting
Conditions
Gastroesophageal Adenocarcinoma
Interventions
Drug: TQB2102 for injection+Benmelstobart
Drug: TQB2102 for injection+Benmelstobart+Capecitabine
First Posted Date
2025-01-10
Last Posted Date
2025-01-10
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Target Recruit Count
168
Registration Number
NCT06767800
Locations
🇨🇳

Fuyang Cancer Hospital, Fuyang, Anhui, China

🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

🇨🇳

The first affiliated hospital of chongqing medical university, Chongqing, Chongqing, China

and more 33 locations

A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

Phase 1
Recruiting
Conditions
Advanced NSCLC
Advanced Endometrial Cancer
Interventions
First Posted Date
2025-01-03
Last Posted Date
2025-01-06
Lead Sponsor
Huabo Biopharm Co., Ltd.
Target Recruit Count
282
Registration Number
NCT06758557
Locations
🇨🇳

Affiliated Hospital of Hebei University / School of Clinical Medicine, Baoding, Hebei, China

🇨🇳

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

🇨🇳

The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan, China

and more 11 locations

Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Phase 3
Recruiting
Conditions
Bietti Crystalline Corneoretinal Dystrophy
Bietti Crystalline Dystrophy
Interventions
First Posted Date
2024-12-20
Last Posted Date
2025-01-03
Lead Sponsor
Chigenovo Co., Ltd
Target Recruit Count
62
Registration Number
NCT06743646
Locations
🇨🇳

Peking University Third Hospital, Beijing, Beijing, China

🇨🇳

Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China

🇨🇳

The First Affiliated Hospital of Harbin Medical University, Haerbin, Heilongjiang, China

and more 5 locations

A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.

Not yet recruiting
Conditions
ALK Positive
Ensartinib
NSCLC
Neoadjuvant Therapy
First Posted Date
2024-12-16
Last Posted Date
2024-12-16
Lead Sponsor
Harbin Medical University
Target Recruit Count
100
Registration Number
NCT06736561

Prospective, Multicenter, Self-controlled Clinical Trial to Validate Optical Ultrasonic Flow Ratio (OUFR)

Not Applicable
Recruiting
Conditions
Fractional Flow Reserve
Coronary Artery Disease
First Posted Date
2024-12-10
Last Posted Date
2024-12-10
Lead Sponsor
Harbin Medical University
Target Recruit Count
114
Registration Number
NCT06726252

A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies

Phase 1
Not yet recruiting
Conditions
Relapsed or Refractory Lymphoid Malignancies
Interventions
Drug: BL-M08D1
First Posted Date
2024-12-05
Last Posted Date
2024-12-05
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
22
Registration Number
NCT06718634
Locations
🇨🇳

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Phase 2
Not yet recruiting
Conditions
Breast Cancer
Interventions
Drug: TQB3616 capsule+Fulvestrant Injection
First Posted Date
2024-11-25
Last Posted Date
2024-12-27
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
33
Registration Number
NCT06702618
Locations
🇨🇳

Jiangmen Central Hospital, Jiangmen, Guangdong, China

🇨🇳

Xingtai People's Hospital, Xingtai, Hebei, China

🇨🇳

Luohe Central Hospital, Luohe, Henan, China

and more 10 locations

Effect of Human Urinary Kallidinogenase on Inflammatory Factors in Acute Ischemic Stroke (KIF-AIS)

Not Applicable
Recruiting
Conditions
Acute Ischemic Stroke
Interventions
Drug: Human urinary kininogenase(HUK)
Other: Placebo
First Posted Date
2024-11-20
Last Posted Date
2024-11-20
Lead Sponsor
First Affiliated Hospital of Harbin Medical University
Target Recruit Count
200
Registration Number
NCT06696703
Locations
🇨🇳

Zhongling Zhang, Harbin, Heilongjiang, China

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Not Applicable
Recruiting
Conditions
Multiple Myeloma
Interventions
First Posted Date
2024-11-20
Last Posted Date
2024-11-25
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
100
Registration Number
NCT06697483
Locations
🇨🇳

Fuxing Hospital, Beijing, Beijing, China

🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

and more 1 locations

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

Phase 2
Recruiting
Conditions
TNBC, Triple Negative Breast Cancer
Interventions
Drug: Neoadjuvant chemotherapy combined with Toripalimab
First Posted Date
2024-11-11
Last Posted Date
2024-11-11
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Target Recruit Count
35
Registration Number
NCT06682195
Locations
🇨🇳

Nanchang People's Hospital, Nanchang, Jiangxi, China

🇨🇳

The First Affiliated Hospital of Anhui Medical University, Anhui, China

🇨🇳

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

and more 10 locations
© Copyright 2025. All Rights Reserved by MedPath